Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kazuhiro Moriyama is active.

Publication


Featured researches published by Kazuhiro Moriyama.


Therapeutic Apheresis and Dialysis | 2011

In Vitro Evaluation of High Mobility Group Box 1 Protein Removal with Various Membranes for Continuous Hemofiltration

M Yumoto; Osamu Nishida; Kazuhiro Moriyama; Yasuyo Shimomura; Tomoyuki Nakamura; Naohide Kuriyama; Yoshitaka Hara; Shingo Yamada

The high mobility group box 1 protein (HMGB1) is an alarmin that plays an important role in sepsis and has been recognized as a promising target with a wide therapeutic window; however, no drugs and devices are currently in practical use. We hypothesized that hemofilters composed of porous membranes or cytokine‐adsorbing membranes could remove HMGB1 from the blood. We performed experimental hemofiltration in vitro using four types of hemofilters composed of different membranes specifically designed for continuous hemofiltration. The test solution was a 1000‐mL substitution fluid containing 100 µg of HMGB1 and 35 g of bovine serum albumin. Experimental hemofiltration was conducted for 360 min in a closed loop circulation system. Among the four membranes, surface‐treated polyacrylonitrile (AN69ST) showed the highest capacity to adsorb HMGB1; it adsorbed nearly 100 µg of HMGB1 in the initial 60 min and showed a markedly high clearance rate (60.8 ± 5.0 mL/min) at 15 min. The polymethylmethacrylate membrane had half of the adsorption capacity of the AN69ST membrane. Although the highest sieving coefficient for HMGB1 was obtained with the high cut‐off polyarylethersulfone membrane, which correlated with a constant filtrate clearance rate, albumin loss was observed. However, no such removal of both HMGB1 and albumin was observed with the polysulfone membrane and tubing. We conclude that continuous hemofiltration using the AN69ST membrane is a promising approach for HMGB1‐related sepsis.


Contributions To Nephrology | 2011

Sustained High-Efficiency Daily Diafiltration Using a Mediator-Adsorbing Membrane (SHEDD-fA) in the Treatment of Patients with Severe Sepsis

Osamu Nishida; Tomoyuki Nakamura; Naohide Kuriyama; Yoshitaka Hara; Miho Yumoto; Yasuyo Shimomura; Kazuhiro Moriyama

Sustained high-efficiency daily diafiltration using a mediator-adsorbing membrane (SHEDD-fA) is an effective, intensive modality for sepsis treatment. Here we describe the effectiveness of SHEDD-fA, which makes the best use of three principles: dialysis, filtration and adsorption, for mediator removal in the treatment of severe sepsis. SHEDD-fA was initiated after adequate fluid resuscitation and catecholamine support had been provided. A large (2.1 m(2)) polymethylmethacrylate membrane dialyzer was placed in the blood circuit. Operation conditions were as follows: blood flow rate 150 ml/min, filtration rate 1,500 ml/h (post-dilution), and dialysate flow rate 300-500 ml/min over 8-12 h daily. 55 consecutive patients with severe sepsis were studied. The following results were obtained: pressure catecholamine index significantly decreased at 3 h after initiation of septic shock, PaO(2)/F(IO2) significantly increased at 1 h after initiation of septic acute respiratory distress syndrome, a significant decrease in interleukin (IL)-6 level for 3 days was observed, and IL-6 was effectively adsorbed in one pass through the filter. The average sequential organ failure assessment score of patients was 10.1 and the mortality at 28 days was 16.4% (46 survived, 9 died). Because SHEDD-fA is an intensive and high-efficiency modality, removal of useful drugs or nutrients may be observed. Despite the fact that removal of useful substances cannot be ignored, we believe that an appropriate stage or timing can be identified so that we can avoid a vicious cycle and use blood purification with effective diffusion, filtration and adsorption. We demonstrate that SHEDD-fA may be an effective, intensive modality for the treatment of patients with severe sepsis and is a possible modality for cytokine modulation therapy.


Therapeutic Apheresis and Dialysis | 2015

Novel Blood Purification System for Regulating Excessive Immune Reactions in Severe Sepsis and Septic Shock: An Ex Vivo Pilot Study

Yoshitaka Hara; Yasuyo Shimomura; Tomoyuki Nakamura; Naohide Kuriyama; Chizuru Yamashita; Yu Kato; Taku Miyasho; Toshikazu Sakai; Shingo Yamada; Kazuhiro Moriyama; Osamu Nishida

Promising results have been reported with blood purification as adjuvant treatment; however, the immunological mechanisms remain unclear. We have been developing a new blood purification system for regulating excessive immune reactions in severe sepsis and septic shock using a granulocyte adsorbing column (Adacolumn [Ada]), and a cytokine‐adsorbing hemofilter (AN69ST hemofilter [AN69]). Fresh porcine blood was circulated for 6 h in five experimental groups including Ada and AN69 to assess the effects of leukocyte adsorption, phagocytic activity and adhesiveness of granulocytes. In the present study, we found that Ada mainly adsorbed granulocytes and monocytes, but not lymphocytes. The phagocytic activity level of granulocytes decreased, and adhesiveness increased, but the number of CD11b‐positive cells markedly decreased in the current system. Elevated cytokine levels (IL‐1β, IL‐8 and IL‐10) at the outlet of Ada were significantly lower than at the outlet of AN69 due to cytokine adsorption. Further studies are needed to better understand cellular interactions.


Therapeutic Apheresis and Dialysis | 2018

Influence of Blood Purification and Differential Injection Sites of Cold Saline on Transpulmonary Thermodilution Values: Hemodynamics During Blood Purification

Takahiro Kawaji; Toshikazu Sakai; Kazuhiro Moriyama; Yoshitaka Hara; Tomoyuki Nakamura; Naohide Kuriyama; Yasuyo Shimomura; Yu Kato; Hidefumi Komura; Chizuru Yamashita; Yasuyoshi Kurimoto; Daisuke Hasegawa; Osamu Nishida

We aimed to investigate the effects of blood purification and cold saline injection sites on the transpulmonary thermodilution values. We measured the cardiac output of eight pigs in every combination of cold saline injection (left jugular and femoral veins) and blood purification sites (right jugular and femoral veins), with or without blood purification. We examined the influence of the difference between the presence and absence of blood purification, vascular sites for blood purification, and sites for cold saline injection on the transpulmonary thermodilution values. Cardiac output measured during blood purification using transpulmonary thermodilution was underestimated; however, there was no difference between vascular sites. Cardiac output measured via injection of cold saline into the femoral vein was higher than that obtained through injection of cold saline into the jugular vein, with or without blood purification.


Blood Purification | 2018

In Vitro Study of Endotoxin Adsorption by a Polymyxin B-Immobilized Fiber Column

Chizuru Yamashita; Kazuhiro Moriyama; Daisuke Hasegawa; Yu Kato; Toshikazu Sakai; Takahiro Kawaji; Yasuyo Shimomura; Yasuyoshi Kurimoto; Mariko Nagata; Osamu Nishida

Background: Polymyxin B-immobilized fiber (PMX-F) columns are used as therapeutic interventions for septic shock. The clinical efficacy has been reported for 2-h applications, but their ability to adsorb endotoxin over longer treatments has not been fully elucidated. We hypothesized that PMX-F columns are capable of endotoxin removal for more than 2 h. Method: We designed closed circuits incorporating either a PMX-F column with an 8.5-mL priming volume (PMX-01R) or a sham-control column, and used inactivated fetal bovine serum as the circulating perfusate. Endotoxin was continuously injected at a fixed rate for 24 h, and perfusate endotoxin concentrations were measured at fixed time points. PMX-01R endotoxin adsorption was calculated from the difference in the endotoxin concentrations. Results: PMX-01R endotoxin adsorption increased continuously in a virtually linear manner. Conclusions: The PMX-01R column showed sustained endotoxin adsorption for at least 24 h. This indicated that PMX-F columns would be capable of clinical endotoxin removal for 24 h.


Critical Care | 2011

In vitro evaluation of HMGB1 removal with various membranes for continuous hemofiltration

M Yumoto; Osamu Nishida; Kazuhiro Moriyama; Yasuyo Shimomura; Tomoyuki Nakamura; Naohide Kuriyama; Yoshitaka Hara; S Yamada; Taku Miyasho


Critical Care | 2011

Sustained high-efficiency daily diafiltration using a cytokine-adsorbing membrane in the treatment of patients with severe sepsis

Osamu Nishida; Tomoyuki Nakamura; Naohide Kuriyama; Yoshitaka Hara; Kazuhiro Moriyama; M Yumoto; Yasuyo Shimomura


Archive | 2018

Evidence and Perspectives on the Use of Polymyxin B-Immobilized Fiber Column Hemoperfusion among Critically Ill Patients

Chizuru Yamashita; Kazuhiro Moriyama; Daisuke Hasegawa; Yoshitaka Hara; Naohide Kuriyama; Tomoyuki Nakamura; Junpei Shibata; Hidefumi Komura; Osamu Nishida


Fujita Medical Journal (Web) | 2016

The influence of extracorporeal circulation on EV1000 monitor hemodynamic parameters at two sites of intravenous cold saline injection

Toshikazu Sakai; Yoshitaka Hara; Yu Kato; Tomoyuki Nakamura; Yasuyo Shimomura; Takahiro Kawaji; Yasuyoshi Kurimoto; Mariko Nagata; Seiko Hayakawa; Hidefumi Komura; Chizuru Yamashita; Junpei Shibata; Kazuhiro Moriyama; Osamu Nishida


F1000Research | 2013

Extracorporeal membrane oxygenation (ECMO): The "MOTOR" of cytokine production?

Yoshitaka Hara; Osamu Nishida; Tomoyuki Nakamura; Sohta Uchiyama; Junpei Shibata; Chizuru Yamashita; Miho Yumoto; Yasuyo Shimomura; Naohide Kuriyama; Natsumi Yasuoka; Mai Ito; Kotaro Kawata; Seiko Hayakawa; Shingo Yamada; Taku Miyasho; Kazuhiro Moriyama

Collaboration


Dive into the Kazuhiro Moriyama's collaboration.

Top Co-Authors

Avatar

Osamu Nishida

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yoshitaka Hara

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Taku Miyasho

Rakuno Gakuen University

View shared research outputs
Top Co-Authors

Avatar

M Yumoto

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar

Junpei Shibata

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge